Dr. Siemers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
545 Barnhill Dr
Emerson Hall #125
Indianapolis, IN 46202Phone+1 317-274-8800- Is this information wrong?
Education & Training
Indiana University School of MedicineResidency, Neurology, 1983 - 1986- Indiana University School of MedicineInternship, Internal Medicine, 1982 - 1983
- Indiana University School of MedicineClass of 1982
Certifications & Licensure
IN State Medical License 1982 - 2025- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 8 citationsPilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2.Chris J. Edgar, Eric Siemers, Paul Maruff, Ronald C. Petersen, Paul S. Aisen, Michael W. Weiner, Bruce Albala> ;Journal of Alzheimer's Disease. 2021 Jan 1
- 2 citationsCognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development.Alette M. Wessels, Chris J. Edgar, Pradeep J. Nathan, Eric Siemers, Paul Maruff, John Harrison> ;Drug Discovery Today. 2021 Jan 21
- 151 citationsAssociation of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.Reisa A. Sperling, Michael C. Donohue, Rema Raman, Chung-Kai Sun, Roy Yaari, Karen C. Holdridge, Eric Siemers, Keith A. Johnson, Paul S. Aisen> ;JAMA Neurology. 2020 Jun 1
- Join now to see all
Journal Articles
- Association of Factors with Elevated Amyloid Burden in Clinically Normal Older IndividualsReisa A Sperling, Eric Siemers, Keith A Johnson, JAMA Neurology
Authored Content
- Association of Factors with Elevated Amyloid Burden in Clinically Normal Older IndividualsApril 2020
Press Mentions
Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s DiseaseOctober 31st, 2022- Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer's DiseaseApril 27th, 2022
- Acumen Rides Aducanumab, Amyloid and Alzheimer's Waves on Its IPO VoyageJune 10th, 2021
- Join now to see all
Grant Support
- Coenzyme Q10 And Remacemide--Evaluation In Huntingtons DiseaseNational Center For Research Resources1998–2002
- R-Methu Glial Neurotrophic Factor In Idiopathic Parkinsons DiseaseNational Center For Research Resources1999
Hospital Affiliations
Indiana University Health University HospitalIndianapolis, Indiana
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
